Mentari Therapeutics, a privately held biotechnology enterprise dedicated to preventing migraines, has successfully secured an additional $200 million through a new private placement.
The private placement is scheduled to finalize immediately before Mentari completes its planned corporate merger with InMed Pharmaceuticals, Inc.
(NASDAQ:INM).
Furthermore, the transaction will close concurrently with a previously announced initial private placement totaling $290 million, bringing massive capital into the newly formed entity.
The substantial capital injection from prominent healthcare investors is specifically aimed at advancing the company's robust portfolio of targeted biological treatments designed to enhance patient outcomes.
